» Articles » PMID: 37492742

JAG1 Enhances Angiogenesis in Triple-negative Breast Cancer Through Promoting the Secretion of Exosomal LncRNA

Overview
Journal Genes Dis
Date 2023 Jul 26
PMID 37492742
Authors
Affiliations
Soon will be listed here.
Abstract

Despite significant improvements in five-year survival rates due to early diagnosis and combination therapy, triple-negative breast cancer (TNBC) treatment remains a major challenge. Finding new and effective targets for diagnosis and drug therapy is urgent for TNBC patients. Jagged-1 (JAG1), one of the canonical ligands of the Notch signaling pathway, is involved in vascular budding and is a poor prognostic factor of TNBC. In this study, combined with quantitative real-time PCR, database analysis, animal experiments, and other means, JAG1 was confirmed to be related to the poor prognosis of TNBC patients. was highly expressed in MDA-MB-231 Bone (231B) cells, with stronger invasion and metastasis ability than MDA-MB-231 (231) cells. Treatment of human vascular endothelial cells (HUVEC) with TNBC conditioned medium showed that TNBC JAG1 promoted the angiogenesis of HUVEC. Next, we detected the exosomes extracted from TNBC conditioned medium and found that JAG1 promoted the exosome secretion from 231 cells via ALIX-RAB11A/RAB35. In addition, we also found that the exosomes from JAG1 overexpressed TNBC cells contained more long non-coding RNA (lncRNA) , and promoted angiogenesis of HUVEC by targeting . Finally, the angiogenesis-promoting effect of JAG1 in TNBC was further investigated by matrix gel assay. In conclusion, we reveal that JAG1 has a pro-invasion effect on TNBC and is involved in microenvironment angiogenesis by promoting exosome secretion and the MALAT1-miR-140-5p-JAG1/VEGFA pathway.

Citing Articles

Immunoregulatory role of exosomal circRNAs in the tumor microenvironment.

Lv C, Chen J, Wang Y, Lin Y Front Oncol. 2025; 15:1453786.

PMID: 40034598 PMC: 11872884. DOI: 10.3389/fonc.2025.1453786.


Crosstalk between GLTSCR1-deficient endothelial cells and tumour cells promotes colorectal cancer development by activating the Notch pathway.

Liu L, Han F, Deng M, Han Q, Lai M, Zhang H Cell Death Differ. 2025; .

PMID: 39870803 DOI: 10.1038/s41418-025-01450-6.


A novel lncRNA AC112721.1 promotes the progression of triple-negative breast cancer by directly binding to THBS1 and regulating miR-491-5p/C2CD2L axis.

Ma P, Kang S, Li H, Li M, Zhao Y, Yuan H Sci Rep. 2024; 14(1):32056.

PMID: 39738500 PMC: 11685780. DOI: 10.1038/s41598-024-83665-0.


Patterns of immune evasion in triple-negative breast cancer and new potential therapeutic targets: a review.

Serrano Garcia L, Javega B, Llombart Cussac A, Gion M, Perez-Garcia J, Cortes J Front Immunol. 2024; 15:1513421.

PMID: 39735530 PMC: 11671371. DOI: 10.3389/fimmu.2024.1513421.


Alteration of skin fibroblast steady state contributes to healing outcomes.

Huang Y, Wang N, Xing H, Tian J, Zhang D, Gao D bioRxiv. 2024; .

PMID: 39713414 PMC: 11661132. DOI: 10.1101/2024.12.06.627278.


References
1.
Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

2.
Li Z, Kang Y . Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther. 2016; 161:79-96. PMC: 4851893. DOI: 10.1016/j.pharmthera.2016.03.003. View

3.
Burke E, Kodumudi K, Ramamoorthi G, Czerniecki B . Vaccine Therapies for Breast Cancer. Surg Oncol Clin N Am. 2019; 28(3):353-367. DOI: 10.1016/j.soc.2019.02.004. View

4.
Ballhause T, Jiang S, Baranowsky A, Brandt S, Mertens P, Frosch K . Relevance of Notch Signaling for Bone Metabolism and Regeneration. Int J Mol Sci. 2021; 22(3). PMC: 7865281. DOI: 10.3390/ijms22031325. View

5.
Sun Z, Yang S, Zhou Q, Wang G, Song J, Li Z . Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer. 2018; 17(1):82. PMC: 5909226. DOI: 10.1186/s12943-018-0831-z. View